Hou, Hsin-An

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 196

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation

Nagase, R., Inoue, D., Pastore, A., Fujino, T., Hou, H.-A., Yamasaki, N., Goyama, S., Saika, M., Kanai, A., Sera, Y., et al. (2018) · Journal of Experimental Medicine

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 155

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Huang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 62

The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome

Yang, Y.-T., Chiu, Y.-C., Kao, C.-J., Hou, H.-A., Lin, C.-C., Tsai, C.-H., Tseng, M.-H., Chou, W.-C., & Tien, H.-F. (2018) · Blood Cancer Journal

RNA Research and SplicingAcute Myeloid Leukemia Research

Cited by 32

Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis

Mascarenhas, J. O., Bose, P., Hou, H.-A., Homenda, W., Ross, D., Mohan, S. R., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Khalina, Y., et al. (2024) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 8